Charles River Laboratories

Selected news for the company - Charles River Laboratories, collected since 4/2020. This company shares news with Medical Research, Zacks Investment Research, Merck, Citigroup and dozens of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 Skandinaviska Enskilda Banken AB publ Grows Position in Charles River Laboratories International, Inc. (NYSE:CRL) - American Banking News American Banking News Skandinaviska Enskilda Banken AB publ raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 482.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 78,082 shares of the medical research company’s stock after purchasing an additional 64,665 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.15% of ...
1/12/2022 Charles River Laboratories International, Inc. (NYSE:CRL) Receives $412.69 Consensus Target Price from Analysts - Mayfield Recorder Mayfield Recorder ... month price objective among brokers that have issued a report on the stock in the last year is $412.69.Several brokerages recently weighed in on CRL. Citigroup dropped their price target on shares of Charles River Laboratories International from $425.00 to $400.00 and set a “neutral” rating on the stock in a research report on Thursday, November 4th. Morgan Stanley dropped their price target on shares of Charles River ...
1/12/2022 Charles River Laboratories International, Inc. (NYSE:CRL) Receives $412.69 Consensus Price Target from Analysts The Markets Daily Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have earned an average recommendation of “Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last ...
1/12/2022 Iridian Asset Management LLC CT Reduces Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Ticker Report Ticker Report Iridian Asset Management LLC CT cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 46.3% in the third quarter, HoldingsChannel reports. The firm owned 110,793 shares of the medical research company’s stock after selling 95,394 shares during the period. Iridian Asset Management LLC CT’s holdings in Charles River Laboratories International were worth $45,721,000 as of its most recent SEC filing.Other hedge funds ...
1/12/2022 Iridian Asset Management LLC CT Sells 95,394 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) Daily Political Iridian Asset Management LLC CT Sells 95,394 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) Posted by Tyrone Williams on Jan 12th, 2022 Share on StocktwitsIridian Asset Management LLC CT reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 46.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 110,793 shares of the medical ...
1/12/2022 The Kane Republican kanerepublican.com Earnings season begins this week as corporations report their Q4 results and wrap up fiscal year 2021. Related Stocks: Charles River Laboratories Intl Citigroup Darden Restaurants Etsy Inc Ford Motor Fortinet Inc Kraft Heinz Company LKQ Corp Lamb Weston Holdings Inc MGM Resorts International Meta Platforms, Inc. Netflix Solaredge Tech Under Armour Wal-Mart Stores, Inc ...
1/12/2022 The Best and Worst of Q4 Earnings post-gazette.com Earnings season begins this week as corporations report their Q4 results and wrap up fiscal year 2021. Related Stocks: Charles River Laboratories Intl Citigroup Darden Restaurants Etsy Inc Ford Motor Fortinet Inc Kraft Heinz Company LKQ Corp Lamb Weston Holdings Inc MGM Resorts International Meta Platforms, Inc. Netflix Solaredge Tech Under Armour Wal-Mart Stores, Inc ...
1/12/2022 The Best and Worst of Q4 Earnings buffalonews.com Earnings season begins this week as corporations report their Q4 results and wrap up fiscal year 2021. Related Stocks: Charles River Laboratories Intl Citigroup Darden Restaurants Etsy Inc Ford Motor Fortinet Inc Kraft Heinz Company LKQ Corp Lamb Weston Holdings Inc MGM Resorts International Meta Platforms, Inc. Netflix Solaredge Tech Under Armour Wal-Mart Stores, Inc ...
1/12/2022 The Best and Worst of Q4 Earnings financialcontent.com Earnings season begins this week as corporations report their Q4 results and wrap up fiscal year 2021. Related Stocks: Charles River Laboratories Intl Citigroup Darden Restaurants Etsy Inc Ford Motor Fortinet Inc Kraft Heinz Company LKQ Corp Lamb Weston Holdings Inc MGM Resorts International Meta Platforms, Inc. Netflix Solaredge Tech Under Armour Wal-Mart Stores, Inc ...
1/12/2022 Biologics Drug Development Market Top Company, Geographical Region, and Industry Segments till2028| Abbvie, Allergan, Boehringer Ingelheim weeklywall.com ... includes company profiling of almost all important players of the global Biologics Drug Development Biologics Drug Development market.Key Players Mentioned in the Global Biologics Drug Development Market Research Report: Abbvie, Allergan, Boehringer Ingelheim, Charles River Laboratories , Catalent, Lonza Group, Amgen, SanofiGlobal Biologics Drug Development Market by Type: Clinical Manufacturing, Formulation Development, Bioassay Development, Analytical Services Biologics Drug DevelopmentGlobal Biologics Drug Development Market by Application: In-House, Outsource ...
1/12/2022 Charles River Laboratories International, Inc. (NYSE:CRL) Expected to Post Quarterly Sales of $891.50 Million thelincolnianonline.com Wall Street brokerages expect Charles River Laboratories International, Inc. (NYSE:CRL) to report $891.50 million in sales for the current quarter, according to Zacks . Five analysts have issued estimates for Charles River Laboratories International’s earnings. The lowest sales estimate is $875.12 million and the highest is $921.78 million. Charles River Laboratories International posted sales of $790.99 million during the same quarter last year, which would indicate a positive year ...
1/11/2022 Taxpayers funded ‘monkey torture’: Fauci angers PETA with transgender research grant worldtribune.com ... NIAID began HIV-related tests on monkeys a year after Fauci took charge of the agency in 1984.Each year, NIAID acquires 400 to 600 rhesus monkeys from a South Carolina island leased by Charles River Laboratories , which has a $27.5 million contract with the Fauci-led agency, the Washington Free Beacon reported on Jan. 10 .Injecting male monkeys with female hormones is “yet another pointless, wasteful monkey torture experiment ...
1/11/2022 From EVs to the metaverse, ETF managers name their hottest stock calls for 2022 streetregister.com ... the metaverse, ETF managers name their hottest stock calls for 2022 CNBC interviewed two ETF managers to find out which stocks they should hold in order to capitalize on current trends. Tagged business news, Charles River Laboratories International Inc, Exchange-traded funds, Horizon Kinetics Inflation Beneficiaries ETF, Intercontinental Exchange Inc, Investing News, Investment strategy, Kuka AG, Lucid Group Inc, Meta Platforms Inc, NVIDIA Corp, Rivian Automotive Inc, Roblox Corp, S ...
1/11/2022 Fauci funded experiment: Injecting female hormones into monkeys to replicate human transgenders thebl.com ... on to describe, “As part of another study, researchers infected beagles with mutated bacteria from ticks.”Additionally, the department purchases an average of 500 rhesus monkeys from a South Carolina island leased by Charles River Laboratories , which has a $27.5 million contract with NIAID.Dr. Katherine Roe, a neuroscientist with the animal rights organization People for the Ethical Treatment of Animals (PETA), strongly criticizes the torture of these animals ...
1/11/2022 TD Asset Management Inc. Decreases Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Stock Observer thestockobserver.com TD Asset Management Inc. cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,449 shares of the medical research company’s stock after selling 46 shares during the quarter. TD Asset Management Inc.’s holdings in Charles River Laboratories International were worth $21,231,000 at the ...
1/11/2022 TD Asset Management Inc. Cuts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Transcript Daily transcriptdaily.com TD Asset Management Inc. lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 51,449 shares of the medical research company’s stock after selling 46 shares during the period. TD Asset Management Inc. owned about 0.10% of Charles River Laboratories International worth $21,231,000 as ...
1/11/2022 Charles River Laboratories Inte – Consensus Indicates Potential 35.0% Upside directorstalkinterviews.com 16 pmCharles River Laboratories Inte found using ticker (CRL) now have 11 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 465 and 400 with a mean TP of 443.73. Given that the stocks previous close was at 328.68 this would indicate that there is a potential upside of 35.0%. There ...
1/11/2022 Charles River Laboratories Announces Chief Financial Officer Retirement and Transition Plan | Business Wire Business Wire WILMINGTON, Mass.--( BUSINESS WIRE )--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a retirement and transition plan for its Chief Financial Officer.David R. Smith, Corporate Executive Vice President and Chief Financial Officer, has announced that following a transition period, he will retire from Charles River after a distinguished career in healthcare and finance leadership roles. Mr. Smith will remain with the Company in his current position until a ...
1/11/2022 Charles River Laboratories Announces Chief Financial Officer Retirement and Transition Plan itbusinessnet.com Charles River Laboratories Announces Chief Financial Officer Retirement and Transition PlanDavid R. Smith, Corporate Executive Vice President & Chief Financial Officer, to Transition Role by End of 2022Charles River Issues 2022 Financial Guidance in Conjunction with J.P. Morgan Healthcare ConferenceWILMINGTON, Mass.–(BUSINESS WIRE)– $CRL CRL –Charles River Laboratories International, Inc. (NYSE: CRL) today announced a retirement and transition plan for its Chief Financial Officer.David R ...
1/11/2022 malvern-online.com Charles River Laboratories International, Inc. ( NYSE: CRL ) today announced a retirement and transition plan for its Chief Financial Officer.David R. Smith, Corporate Executive Vice President and Chief Financial Officer, has announced that following a transition period, he will retire from Charles River after a distinguished career in healthcare and finance leadership roles. Mr. Smith will remain with the Company in his current position until a successor has been named ...